VTVT vs. ASMB, SLS, AFMD, RLYB, CUE, JAGX, HOOK, TPST, SCYX, and BTAI
Should you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include Assembly Biosciences (ASMB), SELLAS Life Sciences Group (SLS), Affimed (AFMD), Rallybio (RLYB), Cue Biopharma (CUE), Jaguar Health (JAGX), Hookipa Pharma (HOOK), Tempest Therapeutics (TPST), SCYNEXIS (SCYX), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical preparations" industry.
vTv Therapeutics (NASDAQ:VTVT) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.
vTv Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
vTv Therapeutics has higher earnings, but lower revenue than Assembly Biosciences.
In the previous week, Assembly Biosciences had 5 more articles in the media than vTv Therapeutics. MarketBeat recorded 6 mentions for Assembly Biosciences and 1 mentions for vTv Therapeutics. Assembly Biosciences' average media sentiment score of 0.03 beat vTv Therapeutics' score of -0.17 indicating that Assembly Biosciences is being referred to more favorably in the news media.
vTv Therapeutics received 109 more outperform votes than Assembly Biosciences when rated by MarketBeat users. However, 59.31% of users gave Assembly Biosciences an outperform vote while only 57.73% of users gave vTv Therapeutics an outperform vote.
17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 1.7% of vTv Therapeutics shares are owned by company insiders. Comparatively, 5.1% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
vTv Therapeutics' return on equity of 0.00% beat Assembly Biosciences' return on equity.
Summary
Assembly Biosciences beats vTv Therapeutics on 8 of the 12 factors compared between the two stocks.
Get vTv Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VTVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
vTv Therapeutics Competitors List
Related Companies and Tools
